BIOMAT Database Logo BIOMAT Database Logo

Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. 1998

F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Department of Internal Medicine I, Division of Infectious Diseases, University of Vienna, A-1090 Vienna, Austria. florian.thalhammer@akhwien.ac.at

The pharmacokinetic properties of meropenem were investigated in nine critically ill patients treated by continuous venovenous hemofiltration (CVVH). All patients received one dose of 1 g of meropenem intravenously. High-flux polysulfone membranes were used as dialyzers. Meropenem levels were measured in plasma and ultrafiltrate by high-performance liquid chromatography. The total body clearance and elimination half-life were 143.7 +/- 18.6 ml/min and 2.46 +/- 0.41 h, respectively. The post- to prehemofiltration ratio of meropenem was 0.24 +/- 0.06. Peak plasma drug concentrations measured 60 min postinfusion were 28.1 +/- 2.7 microgram/ml, and trough levels after 6 h of CVVH were 6.6 +/- 1.5 microgram/ml. The calculated total daily meropenem requirement in these patients with acute renal failure and undergoing CVVH was 2,482 +/- 321 mg. Based on these data, we conclude that patients with severe infections who are undergoing CVVH can be treated effectively with 1 g of meropenem every 8 h.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006440 Hemofiltration Extracorporeal ULTRAFILTRATION technique without HEMODIALYSIS for treatment of fluid overload and electrolyte disturbances affecting renal, cardiac, or pulmonary function. Arteriovenous Hemofiltration,Venovenous Hemofiltration,Arteriovenous Hemofiltrations,Hemofiltration, Arteriovenous,Hemofiltration, Venovenous,Hemofiltrations,Venovenous Hemofiltrations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077731 Meropenem A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients. 3-(5-Dimethylcarbamoylpyrrolidin-3-ylthio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid,Merrem,Penem,Ronem,SM 7338,SM-7338,SM7338
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013845 Thienamycins Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors. Antibiotics, Thienamycin,Thienamycin Antibiotics

Related Publications

F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration.
January 2014, Antimicrobial agents and chemotherapy,
F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Pharmacokinetics of voriconazole during continuous venovenous hemofiltration.
June 2011, Therapeutic drug monitoring,
F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration.
August 2006, The Journal of antimicrobial chemotherapy,
F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration.
January 2015, Antimicrobial agents and chemotherapy,
F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
October 2000, Critical care medicine,
F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.
February 2002, Pharmacotherapy,
F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
January 1999, Clinical pharmacology and therapeutics,
F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction.
August 2016, Neurocritical care,
F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Circuit Survival during Continuous Venovenous Hemodialysis versus Continuous Venovenous Hemofiltration.
January 2020, Blood purification,
F Thalhammer, and P Schenk, and H Burgmann, and I El Menyawi, and U M Hollenstein, and A R Rosenkranz, and G Sunder-Plassmann, and S Breyer, and K Ratheiser
Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients.
April 2012, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!